Bluejay Diagnostics to Present Positive SYMON-I Sepsis Data at SAEM Annual Meeting
Summary
Bluejay Diagnostics announced that an abstract detailing positive clinical data from its SYMON-I study on the Symphony™ IL-6 Test for sepsis has been accepted for presentation at the 2026 SAEM Annual Meeting.
Key Events
-
Abstract Accepted for SAEM Annual Meeting
An abstract related to the Symphony™ IL-6 Test has been accepted for presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting, scheduled for May 18–21, 2026.
-
Positive Pilot Study Data
The presentation will report findings from the SYMON-I pilot clinical study, suggesting that IL-6 levels measured in the emergency department may be associated with subsequent organ dysfunction in sepsis patients.
-
Progress for Lead Product Candidate
This development advances Bluejay's lead product candidate, the Symphony™ IL-6 Test, which is crucial for a company that recently reported substantial doubt about its ability to continue as a going concern.
Analysis
This filing announces the acceptance of an abstract for presentation at a key medical conference, detailing findings from the SYMON-I pilot clinical study. For Bluejay Diagnostics, a company recently disclosing substantial doubt about its ability to continue as a going concern, this positive clinical development for its lead product candidate, the Symphony™ IL-6 Test, is crucial. It provides scientific validation and visibility, which could be instrumental in attracting the necessary capital to address its financial challenges and advance its pivotal SYMON-II study for FDA submission.
At the time of this filing, BJDX was trading at $2.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.9M. The 52-week trading range was $1.70 to $40.80. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.